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Abstract: 
This study is a critical analysis of the association between selective serotonin reuptake inhibitors 
(SSRIs) exposure during pregnancy and autism spectrum disorder (ASD) risk in children. Electronic 
databases were searched for observational studies published from January 1946 to June 2014 related to 
the association between SSRI exposure during pregnancy and ASD in children. Studies relevant to the 
association between SSRI exposure during pregnancy and ASD in children were extracted and 
compiled for meta-analysis evaluation. Ninety-five citations were identified and seven observational 
studies were included. Four case-control studies were eligible for the meta-analysis and two cohort 
studies were narratively reviewed. The pooled crude and adjusted odds ratios of the case-control 
studies were 2.13 (95% CI 1.66-2.73) and 1.81 (95% CI 1.47-2.24) respectively. Low heterogeneity 
was observed between studies. The two population-based cohort studies; utilized the same Denmark 
data set, have conflicting results. The findings of this meta-analysis and narrative review support an 
increased risk of ASD in children of mothers exposed to SSRIs during pregnancy; however, the 
causality remains to be confirmed. 
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Main Text: 
Introduction  
Untreated maternal depression has been associated with poor health outcomes for both 
mothers and children (Sontag-Padilla et al. 2013). Antidepressants are therefore indicated for pregnant 
women if the benefits outweigh the risk (National Institute for Health and Clinical Excellence 2007; 
Joint Formulary Committee 2014). Selective serotonin reuptake inhibitors (SSRIs) are the most 
frequently prescribed anti-depressant classes. Substantial placental transfer occurs with SSRIs 
(Rampono et al. 2009) and may cause unwanted effects to the unborn child. Currently, meta-analysis 
results demonstrate that SSRI exposure during pregnancy is associated with preterm birth and low birth 
rate (Huang et al. 2014), congenital malformation (Myles et al. 2013), and persistent pulmonary 
hypertension (Grigoriadis et al. 2014).  The use of SSRIs in pregnant women is a complex decision that 
requires weighing the effectiveness of treating depressive symptoms while considering potential 
adverse events in mother and child.  
Recent studies have indicated a possible association between the use of SSRIs in pregnancy 
and the risk of autism spectrum disorder (ASD) in children (Croen et al. 2011; Eriksson et al. 2012; 
Gidaya et al. 2014; Harrington et al. 2014; Hviid et al. 2013; Rai et al. 2013; Sorensen et al. 2013). 
SSRIs are able to cross not only the blood-brain barrier for intended pharmacological actions but also 
the placental barrier for possible unintended consequences (Kendall-Tackett and Hale 2010). This is 
evidenced by the high SSRI cord/maternal distribution ratio, i.e., 0.70-0.86 (Rampono et al., 2009). 
Animal studies demonstrate that transient usage of fluoxetine during early development produces 
abnormal emotional behaviors in adult mice, suggesting the role of serotonin transporter modulation 
during development of brain systems involved in emotional and stress related responses (Ansorge et al. 
2004). Pharmacokinetic and pharmacodynamic data, albeit weak and indirect in nature, suggest a 
plausible biological mechanism between in-utero exposure of SSRIs and ASD in children. However, in 
the scientific literature, evidence of this association contradicted several epidemiological studies 
supporting a positive association (Croen et al. 2011; Eriksson et al. 2012; Gidaya et al. 2014; Sorensen 
et al. 2013) whilst others indicated no association (Harrington et al. 2014; Hviid et al. 2013; Rai et al. 
2013). Given conflicting results from studies, it is difficult to reach a consensus as to whether there is a 
link between the use of SSRIs in pregnancy and ASD in children.  
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ASD affects 1 in 88 children in the United States (US) and prevalence is approximately 1 to 
1.2% in the United Kingdom (UK) (Baird et al. 2006; Baron-Cohen et al. 2009). Due to ASD’s early 
onset, their lifelong persistence and associated pervasive impairment (Simonoff et al. 2008), there is 
significant impact on social outcomes, education and health of patients and their families (Bolton et al. 
1998; Buescher et al. 2014). In the US and UK, the cost of supporting an ASD individual with 
intellectual disability throughout their lifetime is estimated to be US$2.2-2.4 million and US$1.4 
million for an ASD individual without intellectual disability (Buescher et al. 2014). Additionally, there 
is a high prevalence of mental health conditions in individuals with ASD, including attention deficit 
hyperactivity disorder, global and specific learning disabilities, emotional disorders, anxiety and 
depressive disorders, and chronic tic disorder (Bradley and Bolton 2006; Green et al. 2005; Simonoff et 
al. 2008). Understanding the risk factors for the development of ASD is an important public health 
issue. 
In view of the above issues, we undertook a systematic review and meta-analysis of published 
observational studies to evaluate whether SSRI exposure during pregnancy increases the risk of ASD in 
children. 
 
Method 
A systematic literature search was conducted using the search terms (SSRI OR Serotonin 
uptake inhibitor OR antidepressant) AND pregnancy AND (autism OR autistic OR pervasive 
developmental disorder OR Asperger syndrome OR Asperger’s syndrome OR ASD). PubMed, 
EMBASE, PsycINFO and the Cochrane Review databases were searched up to 25 June 2014. English 
titles and abstracts were screened and full texts of relevant articles were retrieved for further review to 
identify relevant studies.  A hand-search of selected articles was conducted to further identify pertinent 
studies. This study was conducted in accordance with the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) for the flow chart and the Meta-analysis of Observational 
Studies in Epidemiology (MOOSE) to ensure clear and comprehensive reporting. 
 
Inclusion and exclusion criteria 
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Observational studies, including cohort and case-control study designs, which investigated the 
association between SSRI use and ASD were included.  Case reports and animal studies were 
excluded.  
 
Quality assessment 
As recommended by the Cochrane Collaboration (Higgins and Green 2011), the 
methodological quality of the included studies were assessed using the Newcastle-Ottawa Scale (NOS) 
(Wells et al. 2000). Two authors (HT and LW) independently reviewed and scored each study. Separate 
NOS criteria were used for case control and cohort studies. A maximum of nine stars could be 
allocated for the following categories: selection, comparability and outcome/exposure. The total score 
was obtained by adding the number of stars in the sub-categories where a higher score indicated better 
quality.  
 
Data extraction 
Data from the included studies were extracted using a standardized data collection form. 
These included study duration and design, data source, covariates, exposure groups, and sample size. 
Authors HT and LW independently extracted data and completed the characteristics form that was 
subsequently cross-matched to ensure consistency and accuracy.  
Outcome parameters such as relative risk (RR), crude odds ratio (OR), adjusted OR and the 
corresponding 95% confidence intervals (CI) were extracted and included in the meta-analysis if 
appropriate.  
The primary outcome of interest was the risk or odds of developing ASD following exposure 
to SSRIs, either at preconception, or during pregnancy.  
 
Statistical analysis 
To estimate the association between the use of SSRIs during pregnancy and ASD in children, 
the results of the included studies were combined using DerSimonian and Laird’s random-effects 
model (DerSimonian and Laird 1986) to account for heterogeneity among studies. The Mantel-
Haenszel fixed-effect model was used to validate the results and control for overweighting of the 
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included small studies. All formulations of SSRIs were included. Analysis was performed on both the 
crude and adjusted estimates from the studies. The pooled estimates with 95% CI were calculated. 
 
Sensitivity analysis was performed to assess the robustness of the results. This was conducted 
by substituting the findings of Rai et al. (2013) with those of Eriksson et al. (2012) as the subjects in 
these two studies came from the same data source.  
As the studies included in the analysis were carried out in different settings, we examined the 
extent of heterogeneity among studies with the Cochran Q test (Higgins and Green 2011), where a cut-
off p-value of 0.1 was considered significant for heterogeneity. Higgin’s I2-statistic (Higgins and Green 
2011) was reported for each figure.  
The background incidence rate of ASD was calculated by dividing the total number of ASD 
cases by the total number of people at risk in the respective data source. The corresponding 95% 
confidence intervals were obtained using the Poisson method.  
All probability values (two tailed) with a p-value of 0.05 were considered statistically 
significant. All analyses were conducted using Review Manager 5.2 (Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2012) and SAS version 9.3 (SAS Institute Inc., Cary, 
NC, United States). 
 
Results 
PubMed, EMBASE, PsycINFO and the Cochrane Review databases were searched; yielding 
26, 53, 16 and 0 records respectively, with a total of 95 articles, from 1 January 1946 to 25 June 2014.  
Seventy-one records remained after the removal of duplicates. Titles and abstracts were screened and 
full texts of relevant articles were retrieved for further review with 64 studies meeting the exclusion 
criteria. Seven observational studies (Croen et al. 2011; Eriksson et al. 2012; Gidaya et al. 2014; 
Harrington et al. 2014; Hviid et al. 2013; Rai et al. 2013; Sorensen et al. 2013) were found to be 
relevant to the research question (Figure 1). All the studies used healthcare databases in their analyses. 
Disease codes such as the International Classification of Diseases, Ninth and Tenth Revision (ICD-9 
and ICD-10) were used to identify cases, except for the study of Harrington et al., which used the 
Autism Diagnostic Interview-Revised (ADI-R) and Autism Diagnostic Observation Schedule (ADOS) 
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(Table 1). Included studies were of adequate quality with respect to study design, obtaining more than 
seven out of nine stars from the NOS quality assessment (Table 2). 
Four case-control studies (Croen et al. 2011; Gidaya et al. 2014; Harrington et al. 2014; Rai et 
al. 2013) were eligible for the main meta-analysis, representing a total of 79,221 patients and controls. 
Rai et al. (2013) and Eriksson et al. (2012) used the same database; therefore Eriksson et al. was 
substituted for Rai et al. in a sensitivity analysis. Two cohort studies (Hviid et al. 2013; Sorensen et al. 
2013) that used the same data source were narratively reviewed separately.  
 
Meta-analysis 
Four case-control studies (Croen et al. 2011; Gidaya et al. 2014; Harrington et al. 2014; Rai et 
al. 2013) were meta-analyzed. Two were from US (Croen et al. 2011; Harrington et al. 2014) and the 
others were from Denmark (Gidaya et al. 2014) and Sweden (Rai et al. 2013) (Table 1). The 
commencing years of the studies ranged from 1995 (Croen et al. 2011) to 2010 (Harrington et al. 
2014). In all case-control studies, children without an ASD diagnosis were the controls and samples 
were randomly taken from the corresponding databases (Croen et al. 2011; Gidaya et al. 2014; 
Harrington et al. 2014; Rai et al. 2013; Eriksson et al. 2012). The use of SSRIs during pregnancy was 
significantly associated with an increased risk of ASD in children (pooled crude OR=2.13; 95% CI 
1.66 to 2.73). No heterogeneity was found between studies (Q-statistics=0.5, p=0.92; I2=0%) and thus, 
there was no difference between the random and fixed-effects model (Figure 2). The results remained 
similar and significant using the adjusted OR from each study (pooled adjusted OR=1.81; 95% CI 1.47 
to 2.24) (Figure 3).  
Sensitivity analysis by replacing Rai et al. (2013) with Eriksson et al. (2012) showed similar 
results (pooled crude OR=2.37; 95% CI 1.83 to 3.05) (Figure 4). However, low heterogeneity was 
observed (Q-statistics=3.97, p=0.26; I2=24%) and a slightly different estimate was found from the 
random-effects model (pooled crude OR=2.42; 95% CI 1.74 to 3.37) (Figure 5). 
 
Narrative review 
Two cohort studies were included in this review. Both studies were conducted in Denmark 
using the Danish Civil Registration System, Danish National Prescription Registry and Danish 
Psychiatric Central Register as data sources (Hviid et al. 2013; Sorensen et al. 2013). Hviid et al. 
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conducted a cohort study of all live singletons in Denmark from 1996 to 2005, with follow-up to 2009 
(626,875 births). Through linkage between maternal use of SSRIs and children diagnosed with ASD on 
the Danish database, a survival analysis of time to diagnosis in the children was used to estimate the 
incidence of ASD according to the use of SSRIs in mothers during pregnancy. Hviid et al. identified 
3,892 ASD cases in their cohort with a background incidence rate of 77 per 100,000 person-years. 
Compared with no SSRI exposure, however, the risk of ASD with exposure was not significantly 
increased (adjusted rate ratio=1.20; 95% CI 0.90 to 1.61).  
 Likewise, Sorensen et al. (2013) identified 655,615 children born in their cohort from 1996 to 
2006. Using a similar linkage method, they captured 5,437 children with a diagnosis of ASD, which 
was slightly higher than the rate in Hviid et al. (2013) (0.21% higher; 95% CI 0.18% to 0.24%). In 
contrast, Sorensen et al. (2013) found a significant association between the use of SSRIs during 
pregnancy and the risk of ASD in children (adjusted hazard ratio=1.6; 95% CI 1.3 to 2.0).  
The background incidence rate of ASD was obtained from four studies (Gidaya et al. 2014; 
Hviid et al. 2013; Rai et al. 2013; Sorensen et al. 2013). The rate ranged from 5.91 to 8.48 per 1,000 
patients. Significant differences between the incidence rates were observed (Figure 6). As three out of 
four incidence rates were from the same data source, a pooled estimate was not compiled.  
 
Discussion 
To our knowledge, this is the first systematic review and meta-analysis of SSRI use in 
pregnancy and risk of ASD in children. Based on the results from the meta-analyses of the case control 
studies and review of cohort studies, SSRI exposure during pregnancy appears to be associated with the 
risk of ASD in children. 
Three out of four published case-control studies reported significantly positive association 
between SSRI exposure during pregnancy and ASD in children (Croen et al. 2011; Gidaya et al. 2014; 
Rai et al. 2013). Although Harrington et al. (2014) reported non-significant results for the total sample, 
a statistically significant result was demonstrated when only males were considered. Additionally, 
since the sample size in Harrington et al. (2014) was the smallest of the studies (n=812), the 
statistically non-significant finding may be due to insufficient statistical power.  
The pooled results in our meta-analysis of the four case-control studies (Croen et al. 2011; 
Gidaya et al. 2014; Harrington et al. 2014; Rai et al. 2013) gives an adjusted odds ratio of 1.81 (95% CI 
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1.47-2.24) with low heterogeneity among the studies (I2 = 0.00). The identified studies were conducted 
in several countries (United States, Sweden and Denmark) using different data sources. However, they 
yielded similar results for risk (adjusted OR between 1.55 and 2.2). This lends further support to an 
association between SSRI exposure during pregnancy and ASD in children.  
The two population-based cohort studies which utilized the same Danish dataset had slightly 
different results (Hviid et al. 2013; Sorensen et al. 2013). Sorensen et al. (2013) reports significant 
results (adjusted HR=1.6; 95% CI 1.3-2.0), while Hviid et al. (2013) demonstrated non-significant 
results in the fully adjusted model (adjusted IRR=1.20; 95% CI 0.90-1.61). There were differences 
between the two cohort studies with respect to the number of cases (3,892 in Hviid et al. and 5,437 in 
Sorensen et al.) and the incidence rate of ASD (5.9 per 1,000 patients in Hviid et al. and 8.3 per 1,000 
patients in Sorensen et al.). Both studies share similar inclusion criteria but there were differences in 
the exclusion criteria. One key difference was that Hviid et al. excluded children with genetic 
conditions (Table 1), which may potentially confound the study results, while Sorensen et al. did not. 
By excluding high risk children, it is expected that the number of ASD cases and the incidence rate will 
be lower in Hviid et al., potentially reducing the statistical power to detect an increased risk of less than 
20% in the SSRI treatment group. Alternatively, it is possible that Sorensen et al.’s results are 
confounded by the inclusion of genetic conditions in children. However, it is also worth noting that 
secondary analysis in Hviid et al.’s study showed a statistically significant association between SSRI 
usage 2 years to 6 months before pregnancy and ASD in children (adjusted IRR=1.46; 95% CI 1.17-
1.81).  
Although the results indicate an increased risk of ASD in children exposed to SSRIs during 
pregnancy, we cannot exclude any potential confounding effect on ASD detection in the studies. 
Pregnant women with SSRI exposure are likely to have a greater frequency of medical consultations 
during and after pregnancy compared to non-exposed women (Sontag-Padilla et al. 2013). In turn, their 
children may have more frequent medical encounters compared to other children, which could lead to a 
higher rate of ASD detection. As a result, we cannot exclude the possibility that the positive association 
is due to better detection of ASD in these children. If an increased risk were solely due to better 
detection, we would also expect an increased risk of ASD in children of mothers on other 
antidepressants during pregnancy. Both Croen et al. (2011) and Sorensen et al. (2013) provided 
evidence that this is not the case. Neither identified a significant association between the use of other 
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antidepressants (tricyclics, dual-action antidepressants and serotonin-norepinephrine reuptake 
inhibitors) during pregnancy and the risk of ASD in children (Croen et al. 2011; Sorensen et al. 2013). 
Both studies used medical databases as their data source with a reasonable sample size (1,805 in Croen 
et al and 648,097 in Sorensen et al). Their results do not support the idea that the risk of ASD in 
children will be higher due to greater detection. 
The incidence rate of ASD in four studies were also estimated (Gidaya et al. 2014; Hviid et al. 
2013; Rai et al. 2013; Sorensen et al. 2013) and Hviid et al. was found to have a lower rate (5.91 in 
1,000 patients) despite the same data source as in studies by Sorensen et al. (2013) and Gidaya et al. 
(2014). Variation in Hviid et al.’s (2013) exclusion criteria which excluded children with a number of 
genetic conditions, may have contributed to the difference in ASD incidence rate (Table 1).  
Studies investigating the association between SSRI in pregnancy and the risk of ASD in 
children in the literature are scant, possibly due to difficulties conducting studies in this area. As 
interventional studies would not be ethical in this clinical setting, observational studies appear to be 
more appropriate for investigating this association. However, obtaining a large sample size from a non-
database study is challenging, with long follow-up time in the cohort setting and recall bias in the case-
control setting being major methodological limitations to carrying out and drawing unbiased 
conclusions from such studies. Data linkage between mother and child is not possible or available in 
many databases currently used internationally adding to significant limitations in addressing this 
important association.  
 
Strengths and Limitations 
We undertook a rigorous systematic review and meta-analysis including all relevant literature 
to date. Reviewer selection bias was minimized by using a predefined search strategy for selection and 
data extraction was conducted by two independent authors.  
 Differences in study designs, exclusion criteria, control groups and duration of follow-up can 
affect the accuracy of pooled estimates for both crude and adjusted ORs. However, the findings from 
different case-control studies were consistent with the pooled estimates, which support our findings of 
an increased risk of ASD in children exposed to SSRIs during pregnancy.  
As the number of studies included in the meta-analysis is limited, a funnel plot was not 
performed as it would not reliably identify publication bias. In addition, the studies identified for meta-
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analysis are relatively recent (2011-2014) with similar results; therefore we cannot exclude the 
possibility of publication bias. As a result, the pooled estimates may be overestimated. 
 
Conclusion 
The findings of this meta-analysis and narrative review of epidemiological studies support an 
increased risk of ASD in children exposed to SSRIs during pregnancy; however, causality remains to 
be confirmed. In view of the challenges and difficulties in evaluating this association, further 
replication studies in this area are recommended. 
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Table 1. Characteristics of the included studies 
Study Data Source Study period Country Inclusion criteria Exclusion criteria Control definition 
Exposure 
duration 
definition 
Croen 
2011 
Kaiser Permanente 
Medical Care 
Program in Northern 
California (KPNC) 
1995-
2002 
United 
States 
Born in KPNC facility between 
January 1995 and June 1999; 
remained in health plan for at 
least 2 years following birth; at 
least 1 diagnosis of autism 
(ICD-9-CM code 299.0), 
Asperger syndrome (ICD-9-CM 
code 299.8), pervasive 
developmental disorder not 
otherwise specified (ICD-9-CM 
code 299.8) 
Restricted to 1 child per 
mother; restricted to children 
whose mothers were KPNC 
members with full pharmacy 
benefits in the year before 
delivery; excluded 16 controls 
whose medical records 
contained an ASD diagnosis 
recorded after initial control 
selection 
Children without an 
ASD diagnosis were 
randomly sampled 
from the remaining 
cohort at a ratio of 5 
controls per case 
matched by sex, 
birth year and 
hospital of birth 
Any SSRI 
prescription for 
mothers in the 
year prior to 
delivery 
Eriksson 
2012 
Autism Centre for 
Young Children in 
Stockholm; Swedish 
medical birth register; 
Statistical Central 
Bureau of Sweden 
2002-
2008 
Sweden Registered with a clinical 
diagnosis of ASD between 2005 
and 2008 in the county, drawn 
from a population-based group 
of children; born between 2002 
and 2006 
Families unable to speak 
Swedish or English; children 
moved abroad; children 
referred to general 
rehabilitation centers due to 
complex needs in addition to 
ASD; families declined 
invitation 
Children born alive 
in Stockholm County 
during the period 
2002–2006 without a 
clinical diagnosis of 
ASD 
Any 
antidepressant use 
during pregnancy 
Hviid 
2013 
Danish Medical Birth 
Registry; Danish 
National Prescription 
Registry; Danish 
Psychiatric Central 
Register; Danish 
Civil Registration 
1996-
2010 
Denmark Live births in Denmark during 
the study period of January 1, 
1996, through December 31, 
2005; with known gestational 
age and singleton births      
Children with genetic 
conditions (fragile X syndrome, 
tuberous sclerosis, Angelman’s 
syndrome, Down’s syndrome, 
DiGeorge’s syndrome, 
neurofibromatosis, and Prader–
Willi syndrome) and congenital 
Women without 
SSRI prescriptions 
from 2 years before 
pregnancy through 
delivery 
Any SSRI use 
during the period 
from 4 weeks 
before the 
beginning of the 
pregnancy until 
delivery 
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System rubella syndrome 
Rai 2013 Stockholm Youth 
Cohort; Swedish 
National and 
Regional Register; 
Stockholm County 
Adult Psychiatric 
Outpatient Register; 
Swedish medical 
birth register 
2001-
2007 
Sweden All children 0-17 years old, 
residing in Stockholm County 
between 2001 and 2007 with 
ASD defined by codes from the 
international classification of 
diseases, ninth and tenth 
revisions, ICD-9 (299) and 
ICD-10 (F84), respectively, or 
Diagnostic and Statistical 
Manual of Mental Disorders, 
fourth edition, (299) 
Missing maternal identification 
numbers; adopted children; 
living in Stockholm County less 
than 4 years 
Children in 
Stockholm Youth 
Cohort without ASD 
diagnosis matched 
by sex, birth month 
and birth year in a 
ratio of 1 case to 10 
controls 
Any SSRI use 
reported by 
mothers at their 
first antenatal 
interview 
 
Sorensen 
2013 
Danish Medical Birth 
Registry; Danish 
National Prescription 
Registry; Danish 
Psychiatric Central 
Register; Danish 
Civil Registration 
System; Danish 
National Hospital 
Register 
1996-
2010 
Denmark Antidepressant drugs with ATC 
code N06A with exposure 
window from 30 days before 
conception to the day of birth; 
time of conception after 1 
February 1996 
Children with missing or 
extreme values of gestational 
age (≤ 23 weeks and ≥ 
45weeks) were excluded; 
missing information about 
mothers; adopted children; 
children who died during the 
first year of life 
Women without 
SSRI prescriptions 
from 30 days before 
conception to the day 
of birth 
Any SSRI usage 
from 30 days 
before conception 
to the day of birth. 
Gidaya 
2014 
Danish Drug 
Prescription Register; 
Danish Psychiatric 
Central Register; 
Danish Civil 
Registration System; 
Danish National 
Hospital Register 
1997-
2011 
Denmark Children born in Denmark 
between January 1, 1997 and 
December 31, 2006; All 
biological singletons and one 
child randomly selected from 
multiple births; subjects’ 
records from 1 January 1999 to 
31 March 2011 were searched 
for International Classification 
Children not linked to 
biological mother; mother not 
living in Denmark a year before 
delivery; child's gestational age 
<23 weeks or >43 weeks 
Children from the 
Danish Civil 
Registration System 
without ASD 
admission diagnoses. 
Ten controls per case 
were individually 
matched on birth 
Any SSRI 
exposure from 3 
months prior to 
the estimated date 
of conception to 
birth  
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of Diseases codes (ICD-10) of: 
F840, F841, F845, F848, and 
F849 
month and year 
Harrington 
2014 
CHARGE 
Standardized 
telephone interview 
2003-
2010 
United 
States 
Children with ASD or other 
development disorders aged 2-5 
years old and born in 
California; had at least one 
parent who speaks English or 
Spanish; living with at least one 
biological parent and in 
catchment area of specified 
California Regional Centers 
that coordinate services for 
those with developmental 
disabilities 
Siblings of probands were 
excluded, regardless of case 
status 
Identified using state 
birth files; matched 
to autism cases by 
age, sex and regional 
center (targeted 4:1 
male to female ratio) 
Any SSRI use 3 
months before 
conception to the 
end of pregnancy.  
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Table 2: Quality assessment of the included studies by the Newcastle-Ottawa Scale 
Study Design Selection Comparability Exposure/Outcome Total 
Croen 2011 Case-control **** ** *** 9 
Eriksson 2012 Case-control **** ** ** 8 
Hviid 2013 Cohort **** ** *** 9 
Rai 2013 Case-control **** ** *** 9 
Sorensen 2013 Cohort **** ** *** 9 
Gidaya 2014 Case-control **** ** *** 9 
Harrington 2014 Case-control **** ** * 7 
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Table 3. Summary of results of the included studies  
Study Number of participants Number of events 
Crude 
ORa/RRb/HRc 
Factors considered during adjusted 
analysis 
Adjusted 
OR/RR/HR 
Croen 2011 1805 ASD group: 15 with exposure; 283 without exposure 
Control group: 34 with exposure; 1473 without 
exposure 
2.3 
(95% CId 1.2-4.3) 
Age; race/ethnicity; level of maternal 
education; birth weight; sex; child’s year 
of birth and birth facility 
2.2 
 (95% CI 1.2-4.3) 
Eriksson 
2012 
173578 ASD group: 8 with exposure; 180 without exposure 
Control group: 1714 with exposure; 171676 without 
exposure 
4.45 
(95% CI 2.19-9.05) 
Not available Not available 
Hviid 2013 626875 SSRIs group: 52 with ASD; 6016 without ASD 
Control group: 3752 with ASD; 617055 without ASD 
1.62 
(95% CI 1.23-2.13) 
Age; calendar period; mother’s age at 
birth; country of origin; place of residence; 
parity; psychiatric diagnoses before 
delivery; other drug use during pregnancy; 
smoking status; employment status; level 
of education  
1.20 
(95% CI 0.90-1.61) 
 
 
Rai 2013 47706 ASD group: 14 with exposure; 4415 without exposure 
Control group: 71 with exposure; 43206 without 
exposure 
2.03 
(95% CI 1.13-3.66) 
Maternal age; any maternal psychiatric 
disorder; paternal age; parental income; 
education; occupation; maternal country of 
birth; birth parity 
1.65 
(95% CI 0.90-3.03) 
Sorensen 
2013 
654288 SSRIs group: 91 with ASD; 7415 without ASD 
Control group: 5333 with ASD; 641449 without ASD 
1.9 
(95% CI 1.5-2.4) 
Maternal age at conception; paternal age at 
conception; parental psychiatric history 
(except maternal affective disorder); 
gestational age; birth weight; sex; parity 
1.6 
(95% CI 1.3-2.0) 
Gidaya 2014 57365 ASD group: 76 with exposure; 5139 without exposure 
Control group: 365 with exposure; 51785 without 
exposure 
2.2 
(95% CI 1.6-2.7) 
Parental age; sex of the child; history of 
maternal depression; other SSRI 
indications; child’s birth, month and year 
1.8 
(95% CI 1.4-2.3) 
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Harrington 
2014 
812 ASD group: 29 with exposure; 463 without exposure 
Control group: 11 with exposure; 309 without exposure 
1.52 
(95% CI 0.65-3.53) 
Regional center; child’s year of birth; 
mother’s birthplace  
1.55 
(95% CI 0.59-4.08) 
 
aOR=Odds Ratio 
bRR=Rate Ratio,  
cHR=Hazard Ratio  
d95% CI=95% confidence interval 
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Figure 1: PRISMA Flowchart 
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Figure 2: Meta-analysis of Crude Odds Ratios 
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Figure 3: Meta-analysis of the Adjusted Odds Ratios 
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Figure 4: Sensitivity Analysis: Meta-analysis of Crude Odds Ratios (fixed effect model) 
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Figure 5: Sensitivity Analysis: Meta-analysis of Crude Odds Ratios (random effect model) 
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IR=Incidence rate per one thousand patients 
LCL=95% lower confidence limit 
UCL=95% upper confidence limit 
Sorensen 2013, Gidaya 2014 and Hviid 2013 used the same Danish database; therefore meta-analysis was not 
performed.  
 
Figure 6: Summary Plot of Incidence Rate of ASD 
